After Alexion's Soliris drug missed its primary endpoint in a study of the drug's efficacy as a gMG treatment, Stifel notes that the drug did achieve statistically significant results on three other endpoints., and it says that the missed endpoint was very close to being "clinically meaningful." The firm says that Alexion has "some legitimate hope on the regulatory front" and will likely be able to engage in "a legitimate/serious regulatory dialogue" vis a vis Soliris as a treatment for gMG. It cut its price target on the shares to $195 from $210, but keeps a Buy rating on the stock.